TABLE 3.
WB-indeterminate profiles detected in serum samples from each study group and numbers and percentages of serum samples with HTLV-1/2 infection confirmed by LIA
| WB-indeterminate profilea | No. of samples with profile |
No. of LIA-positive samples (%)b | |||
|---|---|---|---|---|---|
| G1 (n = 48) | G2 (n = 21) | G3 (n = 16) | Total | ||
| GD21, p24 | 10 | 3 | 13 | 12 (92.30) | |
| rgp46 only (I or II) | 5 | 1 | 6 | 5 (83.33) | |
| GD21, p19 | 3 | 3 | 3 | 9 | 8 (88.89) |
| p24, rgp46-II | 4 | 3 | 7 | 7 (100.00) | |
| GD21, rgp46 (I and/or II) | 7 | 1 | 4 | 12 | 9 (75.00) |
| GD21 | 4 | 4 | 6 | 14 | 3 (21.43) |
| p19 | 5 | 5 | 1 (20.00) | ||
| p24 | 4 | 1 | 1 | 6 | 1 (16.67) |
| GD21, p24, rgp46-I | 3 | 3 | 1 (33.33) | ||
| p19, rgp46-I | 1 | 1 | 2 | 2 (100.00) | |
| GD21, gp21, rgp46-II | 1 | 1 | 1 (100.00) | ||
| GD21, p19, p26 | 1 | 1 | 1 (100.00) | ||
| GD21, p24, p32, p36 | 1 | 1 | 1 (100.00) | ||
| p19, p24, rgp46-II | 1 | 1 | 1 (100.00) | ||
| p24, p36, rgp46-II | 1 | 1 | 1 (100.00) | ||
| p19, p24 | 1 | 1 | |||
| p19, p26, p28, p53 | 2 | 2 | |||
a
According to criteria established by the manufacturer of HTLV Blot 2.4 (MP Biomedicals).
b
According to the requirements established by the manufacturer of INNO-LIA HTLV-I/II (Fujirebio).